Journal of Clinical Psychopharmacology

Article	Citations
Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder	38
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior	37
Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs	32
Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers	31
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder	30
Citalopram and Cannabidiol	28
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults	21
The Modernization of Clozapine	21
Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia	21
European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed	20
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder	17
A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression	17
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review	16
Clozapine Response in Schizophrenia and Hematological Changes	16
Clozapine-Associated Myocarditis	16
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users	15
Clozapine	15
Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)	15
Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users	15
Escaping the Long Shadow Cast by Agranulocytosis	15
A Seizure After COVID-19 Vaccination in a Patient on Clozapine	14
Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia	14
Dry Those Crying Eyes	14
Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics	14
Safety and Efficacy in Randomized Controlled Trials of Second-Generation Antipsychotics Versus Placebo for Cognitive Impairments in Schizophrenia	13

Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis	13
Esketamine	13
Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia	13
Risk of Depression Associated With Finasteride Treatment	13
A Chart Audit Study of Clozapine Utilization in Early Psychosis	12
Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic	12
The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia	11
Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs	11
A New Treatment Paradigm	11
Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients	11
One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia	11
Binge Eating Disorders in Antipsychotic-Treated Patients With Schizophrenia	11
Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia	10
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants	10
Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy	10
Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy	10
Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts	10
All in One	10
Prevalence and Appropriateness of Antipsychotic Prescribing in an Italian Prison	10
Effect of Brexpiprazole on Prolactin and Sexual Functioning	9
Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders	9
Plasma Clozapine and Norclozapine After Use of Either Crushed Tablets or Suspension Compared With Tablets	9
The Pitfalls of Psychotropic Polypharmacy	9
Domestic Mass Shooters	9
Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects	9
α-Lipoic Acid as Adjunctive Treatment for Schizophrenia	8
Clozapine Once-Daily Versus Divided Dosing Regimen	8
Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder	8
The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults	8
Evaluation of Emotional Adverse Effects of Antidepressants	8
Clozapine Blood Concentration Predicts Corrected QT-Interval Prolongation in Patients With Psychoses	8
Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning	8
Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression	8
Elevated Clozapine Blood Concentrations After Second COVID-19 Vaccination With Spikevax (COVID-19 Vaccine Moderna)	8
Quetiapine in the Anxiety Dimension of Mood Disorders	8
Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia	8
Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder	8
Drug-Associated Liver Injury Related to Antipsychotics	8
A Single-Blind Randomized Comparison of Lithium and Lamotrigine as Maintenance Treatments for Managing Bipolar II Disorder	8
Methamphetamine-Associated Hyperammonemic Encephalopathy	8
A Real-World Study of Risk Factors for QTc Prolongation in Schizophrenia Patients Receiving Atypical Antipsychotics	7
Antipsychotic-Related Fatal Poisoning, England and Wales, 1993–2019	7
Guideline Adherence of Monitoring Antipsychotic Use for Nonpsychotic Indications in Children and Adolescents	7
Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders	7
Effects of Oxytocin on Emotion Recognition in Schizophrenia	7
How Frequent Is Switching From an Initial Stimulant Family to the Alternative One in the Clinical Setting?	7
Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment	7
Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy	7
Influence of Different Antidepressants on Ocular Surface in Patients With Major Depressive Disorder	7
Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression	7

Prescribing Tamoxifen in Patients With Mood Disorders	7
Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder	7
Adverse Effects After Ayahuasca Administration in the Clinical Setting	7
Esketamine for Unipolar Major Depression With Psychotic Features	7
Melancholic Features in Bipolar Depression and Response to Lamotrigine	7
A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia	6
Psychosis Treatment During COVID-19 Pandemic and the Potential Role of Phenothiazines	6
Prebiotic Treatment Increases Serum Butyrate in People With Schizophrenia	6
Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers	6
Craving Moderates the Effects of Intranasal Oxytocin on Anger in Response to Social Stress Among Veterans With Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder	6
Pramipexole to Improve Cognition in Bipolar Disorder	6
Cost of the Illness of Treatment-Resistant Schizophrenia	6
A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine	6
Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia	6
Ambulatory Heart Rate Variability in Schizophrenia or Depression	6
The Effect of Clozapine on Self-reported Duration of Sleep and Its Interaction With 23 Other Medications	6
High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis	6
Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus	6
Paliperidone-Associated Sialorrhea	6
Structured Interventions to Optimize Polypharmacy in Psychiatric Treatment and Nursing Homes	5
Antidepressant Discontinuation	5
Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents	5
Effect of Cigarette Smoking on Clozapine Dose and on Plasma Clozapine and N-Desmethylclozapine (Norclozapine) Concentrations in Clinical Practice	5
Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole	5
Valproic Acid–Associated Hyperammonemia	5
Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy	5
Catatonia and Delirium	5
Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia	5
Association of Antidepressant Continuation in Pregnancy and Infant Birth Weight	5
No Effect of Coenzyme Q10 on Cognitive Function, Psychological Symptoms, and Health-related Outcomes in Schizophrenia and Schizoaffective Disorder	5
Clozapine and Oral Contraceptives—Implications Beyond Pharmacokinetics	5
Prescription Stimulants and the Risk of Psychosis	5
Calcium Channel Antagonists for Mood Disorders	5
Toxidrome of an Easily Obtainable Nootropic	4
Clinical Utility of Semistructured Interview and Scales to Assess Withdrawal Syndromes With Dose Reduction or Discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reu	4
Hypertensive Emergency and Stroke With Medication Interaction	4
Risk of Mania After Methylphenidate in Patients With Bipolar Disorder	4
Augmentation With Pimavanserin in Treatment Refractory Schizophrenia	4
Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?	4
Central Nervous System Trial Failures	4
Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment	4
Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients	4
Antidepressant-Associated Treatment Emergent Mania	4
Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching	4
Risk of Major Malformations Following First-Trimester Exposure to Olanzapine	4
Genetic Analysis of Clozapine Metabolism in a Patient With Subtherapeutic Clozapine Plasma Concentrations—The Importance of CYP3A5	4
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders	4
Valproate-Associated Hyperammonemic Encephalopathy	4
Prophylactic Management of Women With Bipolar Disorder During Pregnancy and the Perinatal Period	4
Combination With Long-Acting Injectable Antipsychotics and Utilization of Nonstandard Formulations as Compliance Enhancing Methods for Clozapine Users	4
Successful Introduction of Paliperidone Palmitate for Pregnant Woman With Schizophrenia	4
Olanzapine-Related Somnambulism	4
Myocarditis After Clozapine Initiation and mRNA SARS-CoV-2 Vaccination	4
Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration	4
Sertraline-Associated Burning Mouth Syndrome	4
A Withdrawal Syndrome After a Switch of Phenibut to Another γ-Aminobutyric Acid Agonist	4
A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine	4
Case Reports	4
Ketamine for Treatment-Resistant Depression and Suicidality in Adolescents	4
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants	4
Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels	4
The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly	4
Hematological and Other Cancers in People Using Clozapine	4
Polypharmacy Among Patients With Major Depressive Disorder and Co-occurring Substance Use Disorders in a Psychiatric Hospital Setting	4
Lurasidone Augmentation of Clozapine in Refractory Schizophrenia	4
Case Report	4
Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data	4
Use of Sublingual Atropine Drops in Clozapine-Associated Sialorrhea in an Adolescent Patient	4
CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12–17 Years, Wi	4
Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users	4
Antipsychotics and Drug-Induced Liver Injury	3
Serotonin Paradox in Burning Mouth Syndrome	3
Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital	3
Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series	3
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry	3
The Impact of Serotonin Transporter Binding Affinity on the Risk of Bleeding Related to Antidepressants	3
Treatment of Clozapine-Associated Sialorrhea	3
Question	3
Exceptionally High Clozapine-Associated Eosinophilia	3
Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?	3

Physostigmine for Facilitation of Care in Clozapine-Associated Anticholinergic Delirium	3
Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia	3
Vital Sign Changes During Intravenous Ketamine Infusions for Depression	3
Monoamine Oxidase Inhibitors for Trichotillomania	3
Monoamine Oxidase Interactions	3
Novel Use of Clozapine for Nonsuicidal Self-Injury in Adolescent Treatment-Resistant Depression	3
Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia	3
Pharmacokinetics of Ketamine Transfer Into Human Milk	3
Risperidone-Associated Acute Laryngeal Dystonia	3
A Manic Episode With Psychotic Features Associated With Levetiracetam	3
Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia	3
Intravenous Augmentative Valproate Versus Delorazepam in Bipolar Patients With a Major Depressive Mixed Episode and Partial/Nonresponse to Oral Treatment	3
Clozapine-Associated Myocarditis in a Patient With Poor Metabolism During Fast Titration	3
The Effect of Add-on Buprenorphine to Matrix Program in Reduction of Craving and Relapse Among People With Methamphetamine Use Disorder	3
Differential Effectiveness of Atypical Antipsychotics on Hallucinations	3
Should Antipsychotic Medications Be Prescribed to Patients With Nonpsychotic Depression?	3
Valbenazine Treatment of Tardive Dyskinesia and of Positive Symptoms	3
How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block	3
Burning Mouth Syndrome	3
Aripiprazole and Other Third-Generation Antipsychotics as a Risk Factor for Impulse Control Disorders	3
Black Hairy Tongue Associated With Olanzapine Use in a Female Dementia Patient	3
Raising the Quality of Psychopharmacology Clinical Psychiatric Practice	3
Late-Onset Neutropenia With Clozapine Associated With Lithium Carbonate–Related Hyperthyroidism	3
The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder	3
Acute Aripiprazole-Associated Liver Injury	3
Lamotrigine-Associated Hemophagocytic Lymphohistiocytosis	3
Are the Same Medications that Are Used in the Acute Treatment of Depression the Most Suitable for Preventing Relapse?	3
Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases	3
Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia	3
Abilify MyCite (Aripiprazole)	3
Bupropion-Associated Neurotoxicity in Adolescent With Autism Spectrum Disorder on Stable Dose of Amantadine	3
Covert Dyskinesia With Aripiprazole	3
Does the Starting of Clozapine Influence Coprescription of Other Medications?	3
Rapid Improvement of Treatment-Resistant Major Depression During the Administration of Low-Dose Oxycodone	3
Levetiracetam-Associated Obsessive-Compulsive Symptoms in a Preschooler	3
Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder	3
Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder	3